MedImmune Appoints Development Leadership Team
This article was originally published in The Pink Sheet Daily
Former Cambridge Antibody Technology exec to oversee product development.
You may also be interested in...
AstraZeneca Concentrates Biologics At MedImmune, Ups R&D
MedImmune, which absorbs Cambridge Antibody Technologies, will continue to operate independently from AstraZeneca.
AstraZeneca Hears CAT’s Meow With Biotech Acquisition
Deal for Cambridge Antibody Technology, valued at $1.07 bil., will shift focus of AstraZeneca’s pipeline.
Dupixent Succeeds Where Other Biologic Drugs Failed – In COPD
Sanofi and Regeneron could be poised to add another blockbuster indication to the IL-4/IL-13 inhibitor, for chronic obstructive pulmonary disease.